SCHEMBL4724586

SCHEMBL4724586

CCCOc1n[c]oc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
MAPT P10636 5/20 0.37
KDM4E B2RXH2 4/20 0.37
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
MCL1 Q07820 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
GAA P10253 2/20 0.35
CDC7 O00311 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
CHUK O15111 1/20 0.35
PDPK1 O15530 1/20 0.35
DYRK3 O43781 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723120 0.92 MAPK1 (0.42) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4722608 0.87 HPGD (0.41) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4724450 0.78 NPC1 (0.39) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4724587 0.75 MAPT (0.37) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL8848399 0.72 KDM4E (0.37) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4724823 0.72 ALDH1A1 (0.37) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL8848188 0.71 HEXA (0.38) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4719954 0.70 ALDH1A1 (0.35) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL17625982 0.69 SMN1; SMN2 (0.52) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4511404 0.69 BRD4 (0.38) ALDH1A1MAPTHPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 ALDH1A1 622/4885MAPT 4361/4885KDM4E 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.